Mylan Amnesteem Revenue Falls 39%, But Isotretinoin Market Share Stable
Executive Summary
Mylan Amnesteem quarterly revenue fell by more than a third even though the acne drug's share of the isotretinoin market remains fairly stable in the face of increasing competition
You may also be interested in...
Mylan Amnesteem Has 45% Of Isotretinoin Market; Barr’s Claravis Launches
Mylan's generic Accutane has captured roughly half of the isotretinoin market, the company told analysts on a first quarter conference call May 8
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials